Applied Therapeutics (APLT)
(Delayed Data from NSDQ)
$5.24 USD
-0.11 (-2.06%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $5.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APLT 5.24 -0.11(-2.06%)
Will APLT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLT
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Other News for APLT
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
Biotech Alert: Searches spiking for these stocks today
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia
Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases